BioMarin Pharma (BMRN) Tops Q3 EPS, Lowers FY Revenue Guidance

BioMarin Pharma (NASDAQ: BMRN) reported Q3 GAAP EPS of $4.01, which may not compare to the analyst estimate of $1.29. Revenue for the quarter came in at $476.8 million versus the consensus estimate of $454.64 million.

GUIDANCE:

BioMarin Pharma sees FY2020 revenue of $1.81-1.87 billion, versus prior of $1.85-$1.95 billion and the consensus of $1.86 billion.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• BioMarin to acquire Alesta Therapeutics for $275M upfront
• Prenetics Global (PRE) Tops Q2 EPS by 18c